
WAINZUA (eplontersen) EU-Approved for Stage 1/2 Hereditary Transthyretin-Mediated Amyloido
Ionis Pharmaceuticals, Inc. has announced that its partnership with AstraZeneca has led to the approval of WAINZUA (eplontersen) by the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy.…